Modernizing Opioid Treatment Access Act 2.0 of 2026
Summary
HR9790, the Modernizing Opioid Treatment Access Act 2.0, was introduced and referred to two committees on July 20, 2026. It proposes waiving certain methadone dispensing requirements to allow certified practitioners to prescribe methadone for opioid use disorder via pharmacies. The bill is in early legislative stages with no authorized funding, and its market impact is currently negligible.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR9790 is an early-stage regulatory reform bill with no authorized funding.
- 2.It proposes expanding methadone prescribing to pharmacies for opioid use disorder treatment.
- 3.No specific companies or sectors are directly impacted at this stage.
Market Implications
No immediate market implications. The bill does not affect any publicly traded company's revenue or costs. Investors should watch for committee hearings or a companion Senate bill as triggers for further analysis.
Full Analysis
On July 20, 2026, Representative Norcross introduced HR9790, a bill to expand methadone access for opioid use disorder by allowing qualified practitioners to prescribe it for pharmacy dispensing, waiving current restrictions under the Controlled Substances Act. The bill was referred to the Committees on Energy and Commerce and the Judiciary. It has two original cosponsors, including a Republican, indicating some bipartisan support, but it is in the earliest legislative stage with no committee hearings or markup scheduled.
There is no funding amount specified in the bill; it is a regulatory reform that changes prescribing rules rather than authorizing appropriations. The mechanism is a waiver of existing requirements for methadone dispensing, shifting oversight to the Attorney General and HHS Secretary to register qualified practitioners. No direct revenue or cost impact is stated, and no federal procurement or grant programs are created.
No convergence with other signals or procurement is present in the provided data. The bill stands alone as a healthcare regulatory change with no immediate market implications. The legislative path requires committee consideration, potential amendments, House and Senate passage, and presidential action—a multi-year process for a bill at this stage.
Structural winners would be opioid treatment providers and pharmacies if the bill advances, but no specific public companies are directly named or clearly positioned. The bill is too early-stage and lacks financial mechanisms to warrant ticker-level analysis.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $773M Department of Veterans Affairs Contract
TRIWEST HEALTHCARE ALLIANCE CORP: $874M Department of Veterans Affairs Contract
TRIWEST HEALTHCARE ALLIANCE CORP: $903M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $641M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $598M Department of Veterans Affairs Contract
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
Proclamation: Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →